SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
Nvidia Develops New Location-Verification Technology for AI Chips 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
SAN RAMON, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at NobleCon12 - Noble Financial Capital Markets’ Twelfth Annual Investor Conference. The presentation will take place on Monday, January 18, 2015 at 2:30 p.m. ET in Sandpiper Bay, Florida.
The presentation will be webcast and available on the Investors section of the Company's website at http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancer and in a Phase 1b given sequentially with GALE-302. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
[email protected]
